Published in J Virol on March 01, 2003
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol (2003) 4.48
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 1.72
Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol (2005) 1.65
Adenovirus receptors. J Virol (2005) 1.55
Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther (2013) 1.49
Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol (2005) 1.31
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27
Adenovirus. Curr Top Microbiol Immunol (2010) 1.27
Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J Virol (2006) 1.27
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J Virol (2004) 1.15
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther (2006) 1.09
Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol (2005) 1.09
Localization of regions in CD46 that interact with adenovirus. J Virol (2005) 1.08
Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One (2013) 1.05
In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol (2008) 1.03
Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol (2005) 1.00
Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol (2012) 1.00
Lysosomal localization and mechanism of membrane penetration influence nonenveloped virus activation of the NLRP3 inflammasome. Virology (2011) 0.98
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J Virol (2004) 0.97
Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther (2009) 0.95
Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis. PLoS One (2008) 0.93
Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther (2012) 0.92
Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence. PLoS One (2009) 0.90
Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. J Virol (2006) 0.89
Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1. J Virol (2009) 0.88
A Novel Adenoviral Hybrid-vector System Carrying a Plasmid Replicon for Safe and Efficient Cell and Gene Therapeutic Applications. Mol Ther Nucleic Acids (2013) 0.88
Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction. PLoS One (2011) 0.87
Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J Virol (2014) 0.86
Microtubule-mediated and microtubule-independent transport of adenovirus type 5 in HEK293 cells. J Virol (2007) 0.85
Adenovirus membrane penetration: Tickling the tail of a sleeping dragon. Virology (2015) 0.81
The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials (2011) 0.81
Oncolytic viruses: adenoviruses. Virus Genes (2017) 0.81
Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression. Vaccine (2013) 0.80
RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin Exp Immunol (2013) 0.80
Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother (2009) 0.78
Emerging roles for ubiquitin in adenovirus cell entry. Biol Cell (2012) 0.77
Virus infection recognition and early innate responses to non-enveloped viral vectors. Viruses (2010) 0.76
Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. Viruses (2014) 0.76
Influence of cell physiological state on gene delivery to T lymphocytes by chimeric adenovirus Ad5F35. Sci Rep (2016) 0.75
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Endocytosis. Physiol Rev (1997) 7.33
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A (1997) 6.92
Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J Virol (1990) 4.32
Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol (1999) 4.00
Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol (1993) 3.29
PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J (1999) 2.66
Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol (2000) 2.63
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol (2001) 2.56
The role of the adenovirus protease on virus entry into cells. EMBO J (1996) 2.44
Early events in the interaction of adenoviruses with HeLa cells. I. Penetration of type 5 and intracellular release of the DNA genome. Virology (1970) 2.40
The role of the nuclear pore complex in adenovirus DNA entry. EMBO J (1997) 2.37
Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther (1998) 2.27
Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol (2000) 2.14
Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J (2001) 1.98
Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther (2000) 1.97
Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J Virol (1999) 1.96
The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol. J Virol (2000) 1.95
Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol (1997) 1.79
Adenovirus internalization and infection require dynamin. J Virol (1998) 1.78
Second messengers regulate endosomal acidification in Swiss 3T3 fibroblasts. J Cell Biol (1992) 1.74
pH-dependent lysis of liposomes by adenovirus. Biochemistry (1986) 1.74
Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol (2001) 1.70
Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol (1999) 1.59
Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 1.29
Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J Virol (2000) 1.16
Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther (1998) 1.14
On the mechanism of DNA transfection: efficient gene transfer without viruses. Gene Ther (1997) 1.08
Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol (2000) 1.05
A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J Virol (1999) 1.02
Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol (2002) 1.01
The fate of type 7 adenovirions in lysosomes of HeLa cells. Virology (1977) 0.89
CD46 is a cellular receptor for group B adenoviruses. Nat Med (2003) 4.35
Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol (2005) 3.19
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest (2013) 2.04
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther (2007) 1.88
Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 1.72
A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol (2006) 1.65
The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther (2003) 1.63
Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med (2004) 1.54
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther (2005) 1.38
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res (2007) 1.32
Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol (2005) 1.31
Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 1.29
Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J Virol (2007) 1.27
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res (2006) 1.23
Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Mol Ther (2004) 1.22
Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol (2007) 1.20
Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther (2007) 1.18
Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp Hematol (2004) 1.17
Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol (2011) 1.17
Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner. J Virol (2004) 1.15
Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog (2008) 1.13
Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther (2006) 1.09
Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol (2005) 1.09
Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res (2011) 1.09
Localization of regions in CD46 that interact with adenovirus. J Virol (2005) 1.08
Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J Immunol (2005) 1.05
In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol (2008) 1.03
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res (2012) 1.03
Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol (2002) 1.01
A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol (2012) 1.00
Strategies to increase drug penetration in solid tumors. Front Oncol (2013) 0.99
Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther (2010) 0.98
Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res (2002) 0.98
A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette. J Virol (2006) 0.97
In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood (2009) 0.97
Toward a stem cell gene therapy for breast cancer. Blood (2009) 0.97
Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res (2005) 0.96
Receptor usage of a newly emergent adenovirus type 14. Virology (2009) 0.95
The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology (2003) 0.94
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res (2007) 0.92
An adenoviral expression system for AAV rep78 using homologous recombination. Mol Ther (2002) 0.92
A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol (2002) 0.91
Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS Pathog (2013) 0.90
Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors. Biochem Biophys Res Commun (2003) 0.89
Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther (2009) 0.88
A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J Virol (2002) 0.87
Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein. J Gen Virol (2012) 0.85
Identifying functional adenovirus-host interactions using tandem mass spectrometry. Methods Mol Med (2007) 0.85
Structural and functional studies on the interaction of adenovirus fiber knobs and desmoglein 2. J Virol (2013) 0.85
Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. J Virol (2008) 0.83
Tightly regulated gene expression in human hematopoietic stem cells after transduction with helper-dependent Ad5/35 vectors. Exp Hematol (2008) 0.82
Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology (2008) 0.82
Dimerizer-induced proliferation of genetically modified hepatocytes. Mol Ther (2002) 0.81
Restoration of a functional open reading frame by homologous recombination between two adenoviral vectors. Mol Ther (2002) 0.81
Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer. Mol Ther (2012) 0.81
The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials (2011) 0.81
Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Hum Gene Ther (2009) 0.81
Advances in gene transfer into haematopoietic stem cells by adenoviral vectors. Expert Opin Biol Ther (2002) 0.80
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. Mol Ther (2012) 0.80
Development of group B adenoviruses as gene transfer vectors. Biotechnol Genet Eng Rev (2006) 0.79
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. Antivir Ther (2014) 0.79
Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PLoS One (2011) 0.78
Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation. Immunology (2014) 0.78
AAV display--homing in on the target. Nat Biotechnol (2003) 0.78
Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption. Viral Immunol (2014) 0.76
Role of chromatin structure in integration of helper-dependent adenoviral vectors containing the beta-globin locus control region. Hum Gene Ther (2008) 0.76